Sintx Technologies, INC 10-Q quarterly reports

SINTX Technologies reported increased revenue for Q2 2026, but also highlighted substantial doubt about its ability to continue as a going concern, alongside significant operating losses.

SINTX Technologies reports Q3 2025 results, highlighting a strategic shift to biomedical devices, FDA clearance for a new foot and ankle system, and ongoing capital raises amidst declining revenue.

SINTX Technologies reported a wider net loss in Q2 2025 as it strategically shifts focus from industrial to high-margin silicon nitride biomedical devices, despite reduced operating expenses.

SINTX Technologies reports a net loss for Q1 2025, while strategically shifting focus towards biomedical applications and streamlining operations.

SINTX Technologies reported its Q3 2024 financial results, including a net loss, and announced a strategic shift towards the medical device sector, while ceasing operations at its armor plant.

SINTX Technologies saw a significant increase in revenue in the second quarter of 2024, but the company still experienced a net loss and is taking steps to improve operational efficiency.

SINTX Technologies saw a revenue increase in Q1 2024, but continues to face financial challenges and going concern uncertainties.